Investment Rating - The report maintains a "Buy" rating for Yadea Holdings (1585 HK) with a target price of HKD 22.63, indicating a potential upside of 70.8% from the current price of HKD 13.25 [1][2][8]. Core Insights - The company's profitability is driven by a high-end product strategy and accelerated overseas business development. The report highlights a strong recovery in two-wheeler sales in 2025, with a projected year-on-year growth of 25% to 16.27 million units, returning to 2023 levels. Revenue for 2025 is expected to reach RMB 37.01 billion, a 31.1% increase, with net profit soaring by 128.8% to RMB 2.912 billion [6][12]. - The report anticipates a slight sales pressure in the first half of 2026 due to the transition to new national standards, but expects a 6% year-on-year growth in sales for the year overall, with better performance in the second half [6][12]. - The company is focusing on improving its product mix and enhancing gross margins through high-end product offerings, with the average selling price (ASP) for electric bicycles and scooters increasing by 5% and 4% respectively in 2025 [6][12]. - The overseas business is projected to grow, with two-wheeler sales reaching 300,000 units in 2025, accounting for 2% of total sales. The report notes that rising oil prices due to geopolitical uncertainties may accelerate the shift from fuel motorcycles to electric two-wheelers in Southeast Asia [6][12]. Financial Summary - Revenue projections for Yadea Holdings are as follows: - 2024: RMB 28.236 billion - 2025: RMB 37.008 billion - 2026E: RMB 42.049 billion - 2027E: RMB 46.851 billion - 2028E: RMB 52.104 billion - Net profit projections are: - 2024: RMB 1.272 billion - 2025: RMB 3.109 billion - 2026E: RMB 3.482 billion - 2027E: RMB 3.991 billion - 2028E: RMB 4.644 billion [5][12][13]. - The report indicates a projected gross margin improvement to 19.4% in 2026, with a net profit margin of 8.3% [7][12].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][9]. Core Insights - The company achieved a revenue of RMB 21.44 billion for the year 2025, reflecting a year-on-year growth of 26.2%. However, the net profit attributable to shareholders decreased by 54% to RMB 1.205 billion. The adjusted EBITDA was RMB 4.96 billion, up 14.4% year-on-year [6][9]. - The fourth quarter revenue reached RMB 6.25 billion, a 32.7% increase year-on-year, with an adjusted net profit of RMB 850 million, up 7.6% year-on-year [6][9]. - The company plans to continue its IP strategy, with the first proprietary IP "yoyo sauce" generating over RMB 100 million in revenue, and aims to launch 30-40 more IPs in the future [7][9]. Financial Performance Summary - The company reported a total revenue of RMB 21.44 billion for 2025, with a breakdown showing domestic revenue of RMB 10.9 billion (up 16.8%) and international revenue of RMB 8.63 billion (up 29.3%) [7]. - The gross margin remained stable at 44.99%, while the fourth quarter gross margin slightly decreased to 46.39% due to product mix adjustments [7]. - The company’s expenses increased, with the expense ratio rising by 5.75 percentage points to 31.79% for the reporting period, primarily due to increased costs associated with direct stores and IP licensing [7]. Future Projections - For the years 2026 to 2028, the company is projected to achieve net profits of RMB 2.632 billion, RMB 3.419 billion, and RMB 4.091 billion, representing year-on-year growth rates of 118.4%, 30%, and 19.7% respectively [9][10]. - The earnings per share (EPS) are expected to be RMB 2.12, RMB 2.76, and RMB 3.30 for the same period, with corresponding price-to-earnings (P/E) ratios of 13x, 10x, and 8x [9][10].

Investment Rating - The investment rating for the company is "Buy" [2][10]. Core Insights - The report highlights that scale effects support profit recovery, with breakthroughs in overseas energy storage and commercial vehicle businesses, leading to an upward revision of the target price [2][6]. - The target price has been raised to HKD 42.88, indicating a potential upside of 35.4% from the current closing price of HKD 31.66 [1][10]. Financial Performance Summary - Revenue is projected to grow significantly, reaching RMB 68,725 million in 2026, representing a year-on-year increase of 54.8% [5][12]. - Net profit is expected to increase to RMB 2,544 million in 2026, reflecting a growth of 72.4% year-on-year [5][12]. - The gross profit margin is forecasted to be 16.8% in 2026, slightly down from previous estimates due to rising upstream costs [7][12]. Business Segment Insights - The company's revenue from the power battery segment is expected to contribute RMB 303,000 million in 2025, with a year-on-year growth of 55% [6]. - The energy storage battery business is projected to achieve revenue of RMB 141,000 million in 2025, with a remarkable growth rate of 71.9% [6]. - The company anticipates a total shipment volume exceeding 180 GWh in 2026, with significant contributions from both commercial vehicles and energy storage sectors [6][12]. Market Position and Outlook - The company has improved its market share in the global power battery installation to 5.3% in 2025, with a shipment volume of 62.8 GWh, marking a 52.6% increase year-on-year [6]. - The commercial vehicle battery segment is expected to see a substantial increase in deliveries, with projections of 32 GWh in 2026, doubling from the previous year [6]. - The report emphasizes the company's long-term growth potential in the commercial vehicle and energy storage markets, maintaining a positive outlook [6][12].

Investment Rating - The investment rating for the company is "BUY" with a target price of 75 HKD per share [1][5]. Core Insights - The company reported a revenue of 53.7 billion RMB for 2025, a decrease of 4.9% year-on-year, with a net profit of approximately 3.6 billion RMB, down 16% year-on-year. However, the fourth quarter showed a revenue increase of 2.8% year-on-year, reaching 13.83 billion RMB, and a net profit increase of 53.6% year-on-year to 530 million RMB [6][8]. - The duty-free business demonstrated resilience, with duty-free revenue of 39.16 billion RMB in 2025, a slight increase of 1% year-on-year, while taxable revenue decreased by 22% to 13.4 billion RMB [8]. - The company's performance in Hainan benefited from a recovery in market conditions, with total revenue from Sanya, Haikou, and Hainan Free Trade Zone reaching 28.94 billion RMB, a decline of 2% year-on-year, but with a 9.6% increase in the second half of the year [8]. - The gross margin for the year increased by 0.72 percentage points to 33%, primarily due to reduced discounting in Q4, which saw a gross margin increase of 4.8 percentage points year-on-year [8]. - The company expects net profits for 2026 to reach 4.9 billion RMB, representing a year-on-year growth of 36.5%, with projected earnings per share (EPS) of 2.37 RMB [8][10]. Summary by Relevant Sections Financial Performance - The company achieved a net profit of 6.714 billion RMB in 2023, which is expected to decline to 4.893 billion RMB in 2026, before increasing to 6.347 billion RMB by 2028 [10]. - The projected earnings per share (EPS) are expected to be 2.37 RMB in 2026, increasing to 3.07 RMB by 2028 [10]. Market Position - The company holds a significant market position in the duty-free sector, with 100% of its product mix focused on commodity trading [3]. - The stock price as of March 31, 2026, was 64.95 HKD, with a market capitalization of approximately 134.95 billion RMB [2]. Future Outlook - The company anticipates continued growth in the Hainan duty-free market, driven by favorable policies and increased travel during the Spring Festival, with a projected sales increase of 25.9% year-on-year in early 2026 [8]. - The company is entering a new phase of operations with the acquisition of DFS's Greater China business and plans for further optimization in store layout and supply chain management [8].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 32.40, indicating a potential upside of 43.1% from the current price of HKD 22.64 [1][10]. Core Insights - The company is expected to experience high growth driven by BD revenue in 2025, with multiple new products and indications anticipated to be approved, which will help restore product sales to a faster growth trajectory [2]. - The overseas registration of product 707 is progressing rapidly, with milestone revenues expected to continue [2]. - Shareholder returns are projected to strengthen, with plans for increased dividends in 2026 and a special dividend distribution related to the spin-off of a subsidiary [5]. Financial Forecast Changes - Revenue for 2026 is projected at RMB 10,103 million, a decrease of 21% from previous forecasts, with a net profit forecast of RMB 2,467 million, down 45% [4]. - The gross profit margin is expected to be 86.3%, reflecting a decline of 2.0 percentage points from prior estimates [4]. - The company anticipates a recovery in product sales in 2026, with significant contributions from new products and indications [5]. Stock Performance - The stock has shown a 52-week high of HKD 35.90 and a low of HKD 10.12, with a market capitalization of HKD 56,546.80 million [4]. - The stock's year-to-date performance has decreased by 6.37% [4]. Revenue and Profitability Projections - The company forecasts revenues of RMB 10,729 million for 2027 and RMB 11,896 million for 2028, indicating a gradual recovery [11]. - The net profit for 2027 is projected to be RMB 2,626 million, with a slight increase to RMB 2,981 million in 2028 [11]. Cash Flow and Financial Ratios - The company expects to maintain a strong cash position, with cash reserves projected to reach RMB 14,496 million by the end of 2026 [12]. - The gross margin is expected to remain high at 86.3% for 2026, with a net margin of 24.4% [12].

Investment Rating - The investment rating for the company is "Buy" [2][6][10] Core Insights - The company has experienced lower-than-expected performance, with a reported loss of 950 million RMB in 2H25, which is a 69% year-on-year improvement but a 270% increase quarter-on-quarter [6] - The average selling price of polysilicon has decreased to approximately 40,500 RMB per ton, following a government halt on capacity storage plans, which previously led to price increases [6] - The target price has been revised down to 6.30 HKD from 8.62 HKD due to the decline in polysilicon prices, while maintaining a "Buy" rating as the stock is considered undervalued after recent price corrections [6][10] Financial Overview - Revenue projections for the company are as follows: 21,213 million RMB in 2024, 15,254 million RMB in 2025, and 17,188 million RMB in 2026E, reflecting a year-on-year decline of 31.0% and 28.1% for 2024 and 2025 respectively [5][12] - Net profit is expected to improve from a loss of 3,905 million RMB in 2024 to a profit of 1,038 million RMB by 2028 [5][12] - The company’s market capitalization is approximately 1,948.56 million HKD, with a 52-week high of 9.01 HKD and a low of 4.11 HKD [4][10] Business Segment Performance - The polysilicon segment is projected to see sales volumes of 20.3 million tons in 2023, decreasing to 8.3 million tons in 2025, with an expected average selling price of 40,000 RMB per ton in 2026E [8] - The company’s gross margin for polysilicon is expected to remain negative, with projections indicating a gross loss of 1.2 million RMB per ton in 2026E [8] - Investment income is projected at 660 million RMB for 2025, primarily from the sale of power plants and investments in joint ventures [6][12]

Investment Rating - The report maintains a "Buy" rating for the company, Hansoh Pharmaceutical (3692 HK), with a target price adjusted to HKD 44.50, indicating a potential upside of 25.4% from the current price of HKD 35.48 [1][6][10]. Core Insights - The company exceeded expectations in its 2025 performance, with innovative drugs contributing nearly 70% to product sales revenue. The collaboration income has also normalized, enhancing overall performance. The mid-to-late stage pipeline is rich and progressing rapidly, with a new wave of product launches expected starting in 2027, providing greater visibility for long-term growth [2][6]. - The company reported a year-on-year revenue growth of 23% and a net profit growth of 27% for 2025, reaching RMB 15.03 billion and RMB 5.56 billion, respectively. Product sales revenue increased by 20.8%, with innovative drug revenue rising by 30%, accounting for 68% of total sales [6][11]. - The report highlights the efficient advancement of the innovative pipeline, with several key products expected to enter critical phases in 2026. Notable products include HS-20093, HS-20089, HS-20094, and HS-10374, with multiple products set to initiate Phase III or key registration clinical trials this year [6][11]. Financial Performance - The company’s revenue forecast for 2026 is RMB 16.81 billion, with an EBIT of RMB 5.25 billion. The net profit for 2026 is projected to be RMB 5.02 billion, reflecting a slight decrease from 2025 due to increased R&D expenses [11][12]. - The report indicates a continuous increase in R&D investment, expected to rise by over 30% in 2026, with a focus on maintaining a robust pipeline and supporting future growth [6][11]. - The financial ratios indicate a healthy gross margin of approximately 89.7% for 2026, with a net profit margin of 29.9% [12].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 36, indicating a potential upside from the current price of HKD 30.76 [1][5]. Core Insights - The company reported a revenue of RMB 21.44 billion for the year 2025, representing a year-on-year increase of 26.2%. However, the net profit attributable to shareholders decreased by 54% to RMB 1.2 billion. The adjusted EBITDA was RMB 4.96 billion, up 14.4% year-on-year [6][9]. - The company has a strong focus on its IP strategy, with the first proprietary IP "yoyo sauce" generating over RMB 100 million in revenue. The company plans to continue expanding its IP portfolio, with 30-40 IPs in preparation for future growth [7][9]. - The company aims for high double-digit revenue growth in 2026, with a projected net profit of RMB 2.63 billion, reflecting a year-on-year increase of 118.4% [9]. Financial Performance - The company achieved a total revenue of RMB 21.44 billion in 2025, with a breakdown showing domestic revenue of RMB 10.9 billion (up 16.8%) and international revenue of RMB 8.63 billion (up 29.3%) [7]. - The gross margin remained stable at 44.99%, while the fourth quarter gross margin decreased by approximately 0.66 percentage points to 46.39% due to product mix adjustments [7]. - The company plans to continue optimizing store performance and expanding its store network, with a total of 4,568 stores in China and 3,583 overseas [7]. Future Projections - For the years 2026 to 2028, the company is expected to achieve net profits of RMB 2.63 billion, RMB 3.42 billion, and RMB 4.09 billion, respectively, with corresponding year-on-year growth rates of 118.4%, 30%, and 19.7% [9][10]. - The earnings per share (EPS) for the same period are projected to be RMB 2.12, RMB 2.76, and RMB 3.30, with price-to-earnings (P/E) ratios of 13x, 10x, and 8x, respectively [9][10].

Investment Rating - The report maintains a "Buy" rating for Yadea Holdings (01585.HK) [1] Core Views - Yadea achieved record high revenue and profit in 2025, with total revenue of RMB 37.01 billion, a year-on-year increase of 31.1%, and a net profit attributable to shareholders of RMB 2.91 billion, up 128.8% year-on-year [1] - The company is accelerating its high-end product strategy and international expansion, particularly in Southeast Asia, which is expected to open new growth avenues [2][3] - The gross margin reached a historical high of 19.1%, driven by product premiumization and cost optimization [2] Summary by Relevant Sections Performance Overview - In the second half of 2025, Yadea's revenue was RMB 17.82 billion, a year-on-year increase of 28.9%, with a net profit of RMB 1.26 billion, up 429% [1] - Total sales volume reached 16.27 million units in 2025, a 25% increase year-on-year, with an average retail price of RMB 2,275, up RMB 106 from 2024 [2] Product and Market Strategy - High-end products priced above RMB 3,000 accounted for 57.4% of retail sales, with a net profit per unit of approximately RMB 179 [2] - The company is expanding its product lines in electric bicycles, batteries, and three-wheeled vehicles, with significant growth in all categories [2][3] Financial Projections - Expected net profits for 2026, 2027, and 2028 are RMB 3.32 billion, RMB 3.86 billion, and RMB 4.11 billion, representing year-on-year growth rates of 14%, 16%, and 6% respectively [4] - The current price-to-earnings (P/E) ratios for 2026, 2027, and 2028 are projected to be 11, 10, and 9 times [4]

Investment Rating - The report maintains a "Buy" rating for the company, Sanofi Pharmaceutical (1530 HK), with a target price of HKD 32.40, indicating a potential upside of 43.1% from the current price of HKD 22.64 [10][2][5]. Core Insights - The company is expected to experience high growth driven by BD revenue in 2025, with multiple new products and indications anticipated to be approved, which will help restore product sales to a faster growth trajectory [2]. - The overseas registration of product 707 is progressing rapidly, with milestone revenues expected to continue [2]. - Shareholder returns are projected to strengthen, with cash reserves expected to reach RMB 20.4 billion by year-end, doubling from 2024, and plans for increased dividends in 2026 [5][2]. Financial Forecast Changes - Revenue for 2026 is projected at RMB 10,103 million, a decrease of 21% from previous forecasts, with a net profit forecast of RMB 2,467 million, down 45% [4][11]. - The gross profit margin is expected to be 86.3% for 2026, reflecting a decline of 2.0 percentage points from prior estimates [4]. - The company anticipates a recovery in product sales in 2026, with significant contributions from new products and indications [5][2]. Stock Performance - The stock has shown a 52-week high of HKD 35.90 and a low of HKD 10.12, with a market capitalization of HKD 56,546.80 million [4]. - Year-to-date performance has seen a decline of 6.37% [4]. Revenue and Profitability Projections - The company forecasts a gradual increase in revenue from RMB 10,103 million in 2026 to RMB 22,256 million by 2035 [6]. - The EBIT is expected to rise from RMB 2,879 million in 2026 to RMB 7,812 million by 2035, indicating a positive trend in operational profitability [6]. Cash Flow and Financial Ratios - The free cash flow is projected to be RMB 2,472 million in 2026, with a steady increase expected in subsequent years [6]. - The net profit margin is expected to be 24.4% in 2026, with a gradual improvement to 25.1% by 2028 [12].